The Propel bioabsorbable implant family came to Medtronic through its acquisition of IntersectENT in 2022. OM1 and Medtronic partnered on their study to focus on healthcare resource use and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS). They aimed to prove the association of Propel devices with reduced HCRU and surgical revisions after sinus surgery.
Ultimately, the companies hope to use data collected in the study to communicate with payers and expand coverage for the implants.
The companies used OM1s research-grade, real-world data and struck an exclusive partnership with the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF). Medtronic then investigated the impact of Propel devices after ESS on HCRU.
According to a news release, the study connected Propel devices to lower HCRU and revision surgery during 24-month follow-up. The companies concluded that Propel devices may lead to payer savings from reduced healthcare resource utilization.
“The results of this study demonstrate a rare win-win-win within healthcare,” said Amy Van Sach, president of Medtronic ENT. “By reducing postoperative inflammation and follow-up interventions, we have the opportunity to elevate the standard of care for CRS patients, decrease the burden of revision surgeries for physicians, and reduce healthcare utilization costs for the entire industry. OM1’s network of patient journeys within the ENT space were of critical value in our investigation of the impact of PROPEL™ devices on the health utilization of CRS patients.”
